METABOLISM-BASED DRUG INTERACTIONS INVOLVING ORAL AZOLE ANTIFUNGALS IN HUMANS*

REFERENCES

• Bossche H. Vanden. Biochemical targets for antifungal azole derivatives: Hypotesis on the mode of action. Curr. Topics Med. Mycol. 1983; 9: 321–356
   Google Scholar
• Meredith C. G., Maldonado A. L., Speeg K. V. The effect of ketoconazole on hepatic oxidative drug metabolism in the rat in vivo and in vitro. Drug Metab. Disp. 1985; 13: 156–162
   PubMed Web of Science ®Google Scholar
• Mosca P., Bonazzi P., Novelli G., Jezequel A. M., Orlandi F. In vivo and in vitro inhibition of hepatic microsomal drug metabolism by ketoconazole. Br. J. Exp, Pathol. 1985; 66: 737–742
   PubMed Web of Science ®Google Scholar
• Lavrijsen K., Van Houdt J., Thijs D., Meuldermans W., Heykants J. Induction potential of antifungals containing an imidazole or triazole moiety. Biochem. Pharmacol. 1986; 35: 1867–1878
   PubMed Web of Science ®Google Scholar
• La Delfa I., Zhu Q. M., Mo Z., Blaschke T. F. Fluconazole is a potent inhibitor of antipyrine metabolism in vivo in mice. Drug Metab. Disp. 1989; 17: 49–53
   PubMed Web of Science ®Google Scholar
• Lavrijsen K., Van Houdt J., Van Dyck M., Meuldermans W., Heykants J. Induction potential of fluconazole toward drug-metabolizing enzymes in rats. Antimicrob. Agents Chemother. 1990; 34: 402–408
   PubMed Web of Science ®Google Scholar
• Como J. A., Dismukes W. E. Oral azole drugs as systemic antifungal therapy. N. Engl. J. Med. 1994; 330: 263–272
   PubMed Web of Science ®Google Scholar
• Maurice M., Pichard L., Daujat M., et al. Effect of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. FASEB J. 1992; 6: 752–758
   PubMed Web of Science ®Google Scholar
• Ketoconazole. Therapeutic Drugs, C. T. Dollery. Churchill Livingstone, Edinburgh 1991
   Google Scholar
• Fluconazole. Therapeutic Drugs, C. T. Dollery. Churchill Livingstone, Edinburgh 1991
   Google Scholar
• Itraconazole. Therapeutic Drugs, C. T. Dollery. Churchill Livingstone, Edinburgh 1991
   Google Scholar
• Troke P. F., Andrews R. J., Pye G. W. Fluconazole and other azoles: Translation of in vitro activity to in vivo and clinical efficacy. Rev. Infect. Dis. 1990; 12: 276–280
   PubMedGoogle Scholar
• Lin J. H., Lu A. Y. H. Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol. Rev. 1997; 49: 403–449
   PubMed Web of Science ®Google Scholar
• Barone J. A., Kohl J. G., Bierman R. H., et al. Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. Antimicrob. Agents Chemother. 1993; 37: 778–784
   PubMed Web of Science ®Google Scholar
• Ferguson R. M., Sutherland D., Simmons R. L., Najarian J. S. Ketoconazole, cyclosporin metabolism, and renal transplantation. Lancet 1982; 2(8303)882–883
   PubMed Web of Science ®Google Scholar
• Dieperink H., Moller J. Ketoconazole and cyclosporin. Lancet 1982; 2(8309)1217
   PubMed Web of Science ®Google Scholar
• Cunningham C., Burke M. D., Whiting P. H., Simpson J. G., Wheatley D. N. Ketoconazole, cyclosporin, and the kidney. Lancet 1982; 2(8313)1464
   PubMed Web of Science ®Google Scholar
• Daneshmend T. K., Warnock D. W. Clinical pharmacokinetics of ketoconazole. Clin. Pharmacokin. 1988; 14: 13–34
   PubMed Web of Science ®Google Scholar
• Gomez D. Y., Wacher V. J., Tomlanovic S. J., Hebert M. F., Benet L. Z. The effect of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin. Pharm. Ther. 1995; 58: 15–19
   PubMed Web of Science ®Google Scholar
• Lown K. S., Mayo R. R., Leichtman A. B., et al. Role of intestinal P-glycoprotein in interpatient variation in the oral bioavailability of cyclosporine. Clin. Pharm. Ther. 1997; 62: 248–260
   PubMed Web of Science ®Google Scholar
• Odocha O., Kelly B., Trimble S., Murigande C., Toussaint R. M., Callander C. O. Cost-containment strategies in transplantation: The utility of cyclosporine-ketoconazole combination therapy. Transplant. Proc. 1996; 28: 907–909
   PubMed Web of Science ®Google Scholar
• Grant S. M., Clissold S. P. Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs 1990; 39: 877–916
   PubMed Web of Science ®Google Scholar
• Goa K. L., Barradell L. B. Fluconazole: An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Drugs 1995; 50: 658–690
   PubMed Web of Science ®Google Scholar
• Sugar A. M., Saunders C., Idelson B. A., Berland D. B. Interaction of fluconazole and cyclosporine. Ann. Intern. Med. 1989; 110: 844
   PubMed Web of Science ®Google Scholar
• Collignon P., Hurley B., Mitchel D. Interaction of fluconazole with cyclosporin. Lancet 1989; 1(8649)1262
   PubMed Web of Science ®Google Scholar
• Lazar J. D., Wilner K. D. Drug interactions with fluconazole. Rev. Infect. Dis. 1990; 12: S327–S333
   PubMedGoogle Scholar
• Krüger H. U., Schuler U., Zimmerman R., Ehninger G. No severe drug interaction of fluconazole, a triazole antifungal agent, with cyclosporin. Bone Marrow Transpl. 1988; 3(Suppl. 1)271
   Google Scholar
• Kwan J. T. C., Foxall P. J. D., Davidson D. G. C., Bending M. R., Eisinger A. J. Interaction with cyclosporin and itraconazole. Lancet 1987; 2(8553)282
   PubMed Web of Science ®Google Scholar
• Trenk D., Brett W., Jhanchen E., Birnbaum D. Time course of cyclosporin/itraconazole interaction. Lancet 1987; 2(8571)1335–1336
   PubMed Web of Science ®Google Scholar
• Novakova I., Donnelly P., De Witte T., De Pauw B., Boezeman J., Veltman G. Itraconazole and cyclosporin nephrotoxicity. Lancet 1987; 2(8564)20
   Google Scholar
• Kramer M. R. Dose adjustment and cost of itraconazole prophylaxis in lung transplant recipients receiving cyclosporine and tacrolimus (FK506). Transplant. Proc. 1997; 29: 2657–2659
   PubMed Web of Science ®Google Scholar
• Floren L. C., Bekersky I., Benet L. Z., et al. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin. Pharm. Ther. 1997; 62: 41–49
   PubMed Web of Science ®Google Scholar
• Hassan N., Erhsson H. Metabolism of 14C-busulfan in isolated perfused rat liver. Eur. J. Drug Pharmacokinet. 1987; 17: 71
   Google Scholar
• Hassan N., Erhsson H. Urine metabolites of busulfan in the rat. Drug Metab. Disp. 1988; 16: 1856
   Google Scholar
• Marchand D. H., Remmel R. P., Abdel-Monem M. M. Biliary excretion of glutathione conjugate of busulfan and 1,4-diiodobutane in the rat. Drug Metab. Disp. 1993; 16: 85–92
   Google Scholar
• Vassal G., Boland I., Deroussent A., Georgin D., Gouyette A. In vitro busulfan metabolism in human and mouse liver. Proc. Am. Assoc. Cancer Res. 1994; 34: 2995
   Google Scholar
• Buggia I., Zecca M., Alessandrino E. P., et al. Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation. Anticancer Res. 1996; 16: 2083–2088
   PubMed Web of Science ®Google Scholar
• Spina E., Avenoso A., Campo G. M., Scordo M. G., Caputi A. P., Perucca E. Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subject. Br. J. Clin. Pharmacol. 1997; 43: 315–318
   PubMed Web of Science ®Google Scholar
• Ghahramani P., Ellis S. W., Lennard M. S., Ramsay L. E., Tucker G. T. Cytochromes P-450 mediating the N-demethylation of amitriptyline. Br. J. Clin. Pharmacol. 1997; 43: 137–144
   PubMed Web of Science ®Google Scholar
• Nortriptyline. Therapeutic Drugs, C. T. Dollery. Churchill Livingstone, Edinburgh 1991
   Google Scholar
• Newberry D. L., Bass S. N., Mbanefo C. O. A fluconazole/amitriptyline drug interaction in three male adults. Clin. Infect. Dis. 1997; 24: 270–271
   PubMed Web of Science ®Google Scholar
• Gannon R. H., Anderson N. L. Fluconazole–nortriptyline drug interaction. Ann. Pharmacother. 1992; 26: 1456–1457
   PubMed Web of Science ®Google Scholar
• Kronbach T., Mathys D., Umeno M., Gonzales F. J., Meyer U. A. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol. Pharmacol. 1989; 36: 89–96
   PubMed Web of Science ®Google Scholar
• Olkkola K. T., Backman J. T., Neuvonen P. J. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin. Pharmacol. Ther. 1994; 55: 481–485
   PubMed Web of Science ®Google Scholar
• Ahonen J., Olkkola K. T., Neuvonen P. J. Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam. Eur. J. Clin. Pharmacol. 1997; 51: 415–419
   PubMed Web of Science ®Google Scholar
• Ahonen J., Olkkola K. T., Neuvonen P. J. Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers. Br. J. Clin. Pharmacol. 1995; 40: 270–272
   PubMed Web of Science ®Google Scholar
• Von Moltke L. L., Greenblatt D. J., Harmatz J. S., et al. Triazolam biotransformation by human liver microsomes in vitro: Effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J. Pharmacol. Exp. Ther. 1996; 276: 370–379
   PubMed Web of Science ®Google Scholar
• Varh A., Olkkola K. T., Neuvonen P. J. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin. Pharmacol. Ther. 1994; 56: 601–607
   PubMed Web of Science ®Google Scholar
• Wright C. E., Greenblatt D. J., von-Moltke L. L., Ehrenberg B. L., Harmatz J. S., Corbett K. Ketoconazole inhibition of triazolam and alprazolam clearance: Differential kinetic and dynamic consequences. Clin. Pharmacol. Ther. 1997; 61: 183–PII–71
   Google Scholar
• Varhe A., Olkkola K. T., Neuvonen P. J. Fluconazole, but not terbinafine, enhances the effects of triazolam by inhibiting its metabolism. Br. J. Clin. Pharmacol. 1996; 41: 319–323
   PubMed Web of Science ®Google Scholar
• Varhe A., Olkkola K. T., Neuvonen P. J. Effect of fluconazole dose on the extent of fluconazole-triazolam interaction. Br. J. Clin. Pharmacol. 1996; 42: 465–470
   PubMed Web of Science ®Google Scholar
• Neuvonen P. J., Varhe A., Olkkola K. T. The effect of ingestion time interval on the interaction between itraconazole and triazolam. Clin. Pharmacol. Ther. 1996; 60: 326–331
   PubMed Web of Science ®Google Scholar
• Brown M. W., Maldonado A. L., Meredith C. G., Speeg K. V. Effect of ketoconazole on hepatic oxidative drug metabolism. Clin. Pharmacol. Ther. 1985; 37: 290–297
   PubMed Web of Science ®Google Scholar
• Kivisto K. T., Lamberg T. S., Kantola T., Neuvonen P. J. Plasma buspirone concentration are greatly increased by erythromycin and itraconazole. Clin. Pharmacol. Ther. 1997; 62: 348–354
   PubMed Web of Science ®Google Scholar
• Villikka K., Kivisto K. T., Lamberg T. S., Kantola T., Neuvonen P. J. Concentrations and effects of zoplicone are greatly reduced by rifampicin. Br. J. Clin. Pharmacol. 1997; 43: 471–474
   PubMed Web of Science ®Google Scholar
• Jalava K. M., Olkkola K. T., Neuvonen P. J. The effect of itraconazole on the pharmacokinetics and pharmacodynamics of zopiclone. Exp. Toxicol. Pathol. 1996; 48: 357
   Google Scholar
• Jalava K. M., Olkkola K. T., Neuvonen P. J. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zopiclone. Eur. J. Clin. Pharmacol. 1996; 51: 331–334
   PubMed Web of Science ®Google Scholar
• Luurila H., Kivisto K. T., Neuvonen P. J. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zolpidem. Eur. J. Clin. Pharmacol. 1998; 54: 163–166
   PubMed Web of Science ®Google Scholar
• Benedetti M. Strolin, Dostert P. Contribution of amine oxidases to the metabolism of xenobiotics. Drug Metab. Rev. 1994; 26: 507–535
   PubMed Web of Science ®Google Scholar
• Pan L. P., Wijnant P., Vriendt G. De, Rosseel M. T., Belpaire F. M. Characterization of the cytochrome P-450 isoenzymes involved in the in vitro N-dealkylation of haloperidol. Br. J. Clin. Pharmacol. 1997; 44: 557–564
   PubMed Web of Science ®Google Scholar
• Ohnuma T., Iwamoto N., Arai N., et al. A case who had increased plasma-concentrations of haloperidol during itraconazole-treatment. Seishin Igaku 1996; 38: 865–867
   Google Scholar
• Raaska K., Neuvonen P. J. Serum concentrations of clozapine and N-desmethylclozapine are unaffected by the potent CYP3A4 inhibitor itraconazole. Eur. J. Clin. Pharmacol. 1998; 54: 167–170
   PubMed Web of Science ®Google Scholar
• Riva R., Albani F., Contin M., Baruzzi A. Pharmacokinetic interactions between antiepileptic drugs. Clin. Pharmacokinet. 1996; 31: 470–493
   PubMed Web of Science ®Google Scholar
• Schmider J., Greenblatt D. J., von Moltke L. L., Karsov D., Shader R. I. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: Studies of phenytoin p-hydroxylation. Br. J. Clin. Pharmacol. 1997; 44: 495–498
   PubMed Web of Science ®Google Scholar
• Touchette M. A., Chandrasekar P. H., Milad M., Edwards D. J. Contrasting effects of fluconazole and ketoconazole on phenytoin and testosterone disposition in man. Br. J. Clin. Pharmacol. 1992; 34: 75–78
   PubMed Web of Science ®Google Scholar
• Mitchell A. S., Holland J. T. Fluconazole and phenytoin: A predictable interaction. Br. Med. J. 1989; 298: 1315
   PubMed Web of Science ®Google Scholar
• Lazar J. D., Wilner K. D. Drug interactions with fluconazole. Rev. Infect. Dis. 1990; 12: S327–S333
   PubMedGoogle Scholar
• Blum A. R., Wilton J. H., Hilligoss D. M., et al. Effect of fluconazole on the disposition of phenytoin. Clin. Pharmacol. Ther. 1991; 49: 420–425
   PubMed Web of Science ®Google Scholar
• Ducharme M. P., Slaughter R. L., Warbasse L. H., et al. Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin. Clin. Pharmacol. Ther. 1995; 58: 617–624
   PubMed Web of Science ®Google Scholar
• Atiba J. O., Blaschke T. F., Wilkinson G. R. Effects of ketoconazole on the polymorphic 4-hydroxylations of S-mephenytoin and debrisoquine. Br. J. Clin. Pharmacol. 1989; 28: 161–165
   PubMed Web of Science ®Google Scholar
• Guengerich F. P., Brian W. R., Iwasaki M., Sari M. A., Bäärnhielm C., Berntsson P. Oxidation of dihydropyrine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4. J. Med. Chem. 1991; 34: 1838–1844
   PubMed Web of Science ®Google Scholar
• Tailor S. A. N., Gupta A. K., Walker S. E., Shea N. H. Peripheral edema due to nifedipine-itraconazole interaction: A case report. Arch. Dermatol. 1996; 132: 350–352
   PubMed Web of Science ®Google Scholar
• Jalava K. M., Olkkola K. T., Neuvonen P. J. Itraconazole greatly increases plasma concentrations and effects of felodipine. Clin. Pharmacol. Ther. 1997; 61: 410–415
   PubMed Web of Science ®Google Scholar
• Digoxin. Therapeutic Drugs, C. T. Dollery. Churchill Livingstone, Edinburgh 1991
   Google Scholar
• Kauffman C. A., Bagnasco F. K. Digoxin toxicity associated with itraconazole therapy. Clin. Infect. Dis. 1992; 15: 886–887
   PubMed Web of Science ®Google Scholar
• Rex J. Itraconazole-digoxin interaction. Ann. Intern. Med. 1992; 116: 525
   PubMed Web of Science ®Google Scholar
• Sachs M. K., Blanchard L. D., Green P. J. Interaction of itraconazole and digoxin. Clin. Infect. Dis. 1993; 16: 400–403
   PubMed Web of Science ®Google Scholar
• McClean K. L., Sheehan G. J. Interaction between itraconazole and digoxin. Clin. Infect. Dis. 1994; 18: 259–260
   PubMed Web of Science ®Google Scholar
• Alderman C. P., Allcroft P. D. Digoxin interaction. Ann. PharmacoTher. 1997; 31: 438–440
   PubMed Web of Science ®Google Scholar
• Jalava K. M., Partanen J., Neuvonen P. J. Digoxin + itraconazole: Drug interaction. Therapie 1995; 50: S185
   PubMedGoogle Scholar
• Antila S., Karisson M., Lehtonen L., Honkanen T., Neuvonen P. J. Effect of itraconazole on pharmacokinetics of the calcium-sensitizing drug levosimendan. Therapie 1995; 50: S460
   Google Scholar
• Neuvonen P. J., Jalava K. M. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin. Pharmacol. Ther. 1996; 60: 54–61
   PubMed Web of Science ®Google Scholar
• Lees R. S., Less A. M. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. N. Engl. J. Med. 1995; 333: 664
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T., Gorham L. M., Bennet M. A., et al. In vitro metabolism of simvastatin in humans: Identification of metabolizing enzymes and effect of the drug on hepatic P450S. Drug Metab. Disp. 1997; 25: 1191–1199
   PubMed Web of Science ®Google Scholar
• Lovastatin. Therapeutic Drugs, C. T. Dollery. Churchill Livingstone, Edinburgh 1991
   Google Scholar
• Simvastatin. Therapeutic Drugs, C. T. Dollery. Churchill Livingstone, Edinburgh 1991
   Google Scholar
• Horn N. Coadministration of itraconazole with hypolipidemic agents may induce rhabdomyolysis in healthy individuals. Arch. Dermatol. 1996; 132: 1254
   PubMed Web of Science ®Google Scholar
• Segaert N. F., Soete C. De, Vanderwiele I., Verbanck J. Drug-interaction-induced rhabdomyolysis. Nephrol. Dialysis Transplant 1996; 11: 1846–1847
   PubMed Web of Science ®Google Scholar
• Neuvonen P. J., Kantola T., Kivistö K. T. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin. Pharm. Ther. 1998; 63: 332–341
   PubMed Web of Science ®Google Scholar
• Abolfathi Z., Pakdel H., Beaune P., Turgeon J. CYP1A2 is the major involved N-oxidation of mexiletine in man. Clin. Pharmacol. Ther. 1995; 57: 215
   Web of Science ®Google Scholar
• Ueno K., Yamaguchi R., Tanaka K. Lack of kinetic interaction between fluconazole and mexiletine. Eur. J. Clin. Pharmacol. 1996; 50: 129–131
   PubMed Web of Science ®Google Scholar
• Kunze K. L., Wienkers L. C., Thummel K. E., Trager W. F. Warfarin-fluconazole I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: In vitro studies. Drug Metab. Disp. 1996; 24: 414–421
   PubMed Web of Science ®Google Scholar
• Stearns R. A., Chakravarty P. K., Chen R., Chiu S. H. Lee. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Drug Metab. Disp. 1995; 23: 207–215
   PubMed Web of Science ®Google Scholar
• McCrea J. B., Lo M. W., Furtek C. I., et al. Ketoconazole does not effect the systemic conversion of losartan to E-3174. Clin. Pharmacol. Ther. 1994; 59: 169–PII–44
   Google Scholar
• Kazierad D. J., Martin D. E., Blum R. A., et al. Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers. Clin. Pharmacol. Ther. 1997; 62: 417–425
   PubMed Web of Science ®Google Scholar
• Lukkari E., Juhakoski A., Aranko K., Neuvonen P. J. Itraconazole moderately increases serum concentrations of oxybutynin but does not affect those of the active metabolite. Eur. J. Clin. Pharmacol. 1997; 52: 403–406
   PubMed Web of Science ®Google Scholar
• Böttiger Y., Tybring G., Götharson E., Bertilsson L. Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. Clin. Pharmacol. Ther. 1997; 62: 384–391
   PubMed Web of Science ®Google Scholar
• Ahmad S. R., Wolfe S. M. Cisapride and torsades de pointes. Lancet 1995; 345: 312
   Google Scholar
• Chan-Thompkins N. H., Babinchak T. J. Cardiac arrhythmias associated with coadministration of azole compound and cisapride. Clin. Infect. Dis. 1997; 24: 1285
   PubMed Web of Science ®Google Scholar
• Wysowski D. K., Bacsanyi J. Cisapride and fatal arrhythmia. N. Engl. J. Med. 1996; 335: 290–291
   PubMed Web of Science ®Google Scholar
• Yamazaki H., Shimada T. Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R- and S-warfarin enantiomers. Biochem. Pharmacol. 1997; 54: 1195–1203
   PubMed Web of Science ®Google Scholar
• Brass C., Galgiani J. N., Blaschke T. F., Defelice R., O’Reilly R. A., Stevens D. A. Disposition of ketoconazole, an oral antifungal, in humans. Antimicrob. Agents Chem. 1982; 21: 151–158
   PubMed Web of Science ®Google Scholar
• Smith A. G. Potentiation of oral anticoagulants by ketoconazole. Br. Med. J. 1984; 288: 188
   PubMed Web of Science ®Google Scholar
• Black D. J., Kunze K. L., Wienkers L. C., Gidal B. E. Warfarin–fluconazole II. A metabolically based drug interaction: In vitro studies. Drug Metab. Disp. 1996; 24: 422–428
   PubMed Web of Science ®Google Scholar
• Yeh J., Soo S. C., Summerton C. T., Richardson C. Potentiation of action of warfarin by itraconazole. Br. Med. J. 1990; 301: 669
   PubMed Web of Science ®Google Scholar
• Haria M., Bryson H. M., Goa K. L. Itraconazole. Drugs 1996; 51: 585–620
   PubMed Web of Science ®Google Scholar
• Nicoumalone. Therapeutic Drugs, C. T. Dollery. Churchill Livingstone, Edinburgh 1991
   Google Scholar
• Isalska B. J., Stanbridge T. N. Fluconazole in the treatment of candidal prosthetic valve endocarditis. Br. Med. J. 1988; 297: 178–179
   PubMed Web of Science ®Google Scholar
• Veronese M. E., Mackenzie P. I., Doecke C. J., McManus M. E., Miners J. O., Birkett D. J. Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. Biochem. Biophys. Res. Commun. 1991; 175: 1112–1118
   PubMed Web of Science ®Google Scholar
• Veronese M. E., Miners J. O., Randles D., Gregov D., Birkett D. J. Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers. Clin. Pharmacol. Ther. 1990; 47: 403–411
   PubMed Web of Science ®Google Scholar
• Krishnaiah Y. S. R., Satyanarayana S., Visweswaram D. Interaction between tolbutamide and ketoconazole in healthy subjects. Br. J. Clin. Pharmacol. 1994; 37: 205–207
   PubMed Web of Science ®Google Scholar
• Back D. J., Tjia J. F., Karbwang J., Colbert J. In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines. Br. J. Clin. Pharmacol. 1988; 26: 23–29
   PubMed Web of Science ®Google Scholar
• Back D. J., Stevenson P., Tjia J. F. Comparative effects of two antimycotic agents, ketoconazole and terbinafine on the metabolism of tolbutamide, ethinyloestetradiol, cyclosporin and ethoxycoumarin by human liver microsomes in vitro. Br. J. Clin. Pharmacol. 1989; 28: 166–170
   PubMed Web of Science ®Google Scholar
• Kunze K. L., Trager W. F. Warfarin–fluconazole III. A rational approach to management of a metabolically based drug interaction. Drug Metab. Disp. 1996; 24: 429–435
   PubMed Web of Science ®Google Scholar
• Fournier J. P., Schneider S., Martinez P., et al. Coma hypoglycémique chez une patiente traitée par glipizide et fluconazole: Une possible interaction?. Therapie 1992; 47: 433–447
   PubMedGoogle Scholar
• Lazar J. D., Wilner K. D. Key drug interaction studies with fluconazole. Conference Abs., Canada, 1989
   Google Scholar
• Cribb A. E., Spielberg S. P., Griffin G. P. N4-hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P4502C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes. Drug Metab. Disp. 1995; 23: 406–414
   PubMed Web of Science ®Google Scholar
• Gill H. J., Maggs J. L., Madden S., Pirmohamed M., Park B. K. The effect of fluconazole and ketoconazole on the metabolism of sulphamethoxazole. Br. J. Clin. Pharmacol. 1996; 42: 347–353
   PubMed Web of Science ®Google Scholar
• Mitra A. K., Kenneth E. T., Kalhorn T. F., Kharasch E. D., Unadkat J. D. Inhibition of sulfamethoxazole hydroxylamine formation by fluconazole in human liver microsomes and healthy volunteers. Clin. Pharmacol. Ther. 1996; 59: 332–340
   PubMed Web of Science ®Google Scholar
• Strolin M. Benedetti, Inducing properties of rifabutin, and effects on the pharmacokinetics and metabolism of concomitant drugs. Pharmacol. Res. 1995; 32: 177–187
   PubMed Web of Science ®Google Scholar
• Reinach B., de Sousa G., Dostert P., Ings B., Gugenheim J., Rahmani R. Effect of rifabutin on cytochromes P450 and glucoronosyltransferases activities in human hepatocyte cultures. ISSX Proc. 1997; 11: 172
   Google Scholar
• Cocchiara G., Benedetti M. Strolin, Vicario G. P., et al. Urinary metabolites of rifabutin, a new antimycobacterial agent, in human volunteers. Xenobiotica 1989; 19: 769–780
   PubMed Web of Science ®Google Scholar
• Utkin I., Koudriakova T., Thompson T., et al. Isolation and identification of major urinary metabolites of rifabutin in rats and humans. Drug Metab. Disp. 1997; 25: 963–969
   PubMed Web of Science ®Google Scholar
• Trapnell C. B., Jamis-Dow C., Klecker R. W., Collins J. M. Metabolism of rifabutin and its 25-desacetyl metabolite, LM565, by human liver microsomes and recombinant human cytochrome P-450 3A4: Relevance to clinical interaction with fluconazole. Antimicrob. Agents Chem. 1997; 41: 924–926
   PubMed Web of Science ®Google Scholar
• Benedetti M. Strolin, Efthymiopoulos C., Sassella D., Moro E., Repetto M. Autoinduction of rifabutin metabolism in man. Xenobiotica 1990; 20: 1113–1119
   PubMed Web of Science ®Google Scholar
• Trapnell C. B., Nrang P. K., Li R., et al. Fluconazole increases rifabutin (RIF) absorption in HIV (+) patients on stable zidovudine (ZDV) therapy. Proc. 9th Int. Conf. AIDS, Berlin, 1993, 504
   Google Scholar
• Trapnell C. B., Nrang P. K., Li R., Lavelle J. P. Increased plasma rifabutin levels with concomitant fluconazole therapy in HIV-infected patients. Ann. Intern. Med. 1996; 124: 573–576
   PubMed Web of Science ®Google Scholar
• Narang P. K., Trapnell C. B., Schoenfelder J. R., Lavelle J. P., Bianchine J. R. Fluconazole and enhanced effect of rifabutin prophylaxis. N. Engl. J. Med. 1995; 330: 1316–1317
   Web of Science ®Google Scholar
• Gioulekas J., Hall A. Uveitis associated with rifabutin therapy. J. Ophtalmol. 1995; 23: 319–321
   Web of Science ®Google Scholar
• Lefort A., Launay O., Carbon C. Uveitis associated with rifabutin prophylaxis and itraconazole therapy. Ann. Intern. Med. 1996; 125: 939–940
   PubMed Web of Science ®Google Scholar
• Benedetti M. Strolin, Dostert P. Induction and autoinduction properties of rifamycin derivatives: A review of animal and human studies. Environ. Health Perspect 1994; 102: 101–105
   Web of Science ®Google Scholar
• Engelhard D., Stutman H. R., Marks M. I. Interaction of ketoconazole with rifampin and isoniazid. N. Engl. J. Med. 1996; 311: 1681–1683
   Google Scholar
• Jaruratanasirikul S., Kleepkaew A. Lack of effect of fluconazole on the pharmacokinetics of rifampicin in AIDS patients. J. Antimicrob. Chem. 1996; 38: 877–880
   PubMed Web of Science ®Google Scholar
• Kumar G. N., Rodrigues A. D., Buko A. M., Denissen J. F. Cytochrome P450-mediated metabolism of the HIV protease inhibitor ritonavir (ABT-538) in human liver microsomes. J. Pharmacol. Exp. Ther. 1996; 277: 423–431
   PubMed Web of Science ®Google Scholar
• Cato A., III, Cao G., Hsu A., Cavanaugh J., Leonard J., Granneman R. Evaluation of the effect of fluconazole on the pharmacokinetics of ritonavir. Drug Metab. Disp. 1997; 25: 1104–1106
   PubMed Web of Science ®Google Scholar
• McCrea J., Woolf E., Sterrett A., et al. Effects of ketoconazole and other P-450 inhibitors on the pharmacokinetics of indinavir. Pharm. Res. 1996; 13: S485
   PubMedGoogle Scholar
• Sahai J., Gallicano K., Pakuts A., Cameron D. W. Effect of fluconazole on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus. J. Infect. Dis. 1994; 169: 1103–1107
   PubMed Web of Science ®Google Scholar
• Bozzette S. A., Larsen R. A., Chiu J., et al. A placebo controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal mengitis in the acquired immunodeficiency syndrome. N. Engl. J. Med. 1991; 324: 580–584
   PubMed Web of Science ®Google Scholar
• Knupp C. A., Brate D. C., Relue J., Barbhaiya R. H. Pharmacokinetics of didanosine ketoconazole after coadministration to patients seropositive for the human immunodeficiency virus. J. Clin. Pharmacol. 1993; 33: 912–917
   PubMed Web of Science ®Google Scholar
• Bruzzese V. L., Gillum J. G., Israel D. S., Jhonson G. L., Kaplowitz L. G., Polk R. E. Effect of fluconazole on pharmacokinetics of 2′,3′-dideoxynosine in persons seropositive for human immunodeficiency virus. Antimicrob. Agents Chem. 1995; 39: 1050–1053
   PubMed Web of Science ®Google Scholar
• McNulty R. M., Lazor J. A., Sketch M. Transient increase in plasma quinidine concentrations during ketoconazole–quinidine therapy. Clin. Pharmacol. 1989; 8: 222–225
   PubMedGoogle Scholar
• Kaukonen K. M., Olkkola K. T., Neuvonen P. J. Itraconazole increases plasma concentrations of quinidine. Clin. Pharmacol. Ther. 1997; 62: 510–517
   PubMed Web of Science ®Google Scholar
• Yun C. H., Okerholm R. A., Guengerich F. P. Oxidation of the antihistaminic drug terfenadine in human liver microsomes, role of cytochrome P450 3A(4) in N-dealkylation and C-hydroxylation. Drug Metab. Disp. 1993; 21: 403–409
   PubMed Web of Science ®Google Scholar
• Ling K. J., Leeson G. A., Burmaster S. D., Hook R. H., Reith M. K., Cheng L. K. Metabolism of terfenadine associated with CYP3A4 activity in human hepatic microsomes. Drug Metab. Disp. 1995; 23: 631–636
   PubMed Web of Science ®Google Scholar
• Li A. P. Drug-drug interactions: Scientific and regulatory perspectives. Adv. Pharmacol. 1997; 43: 103–130
   PubMedGoogle Scholar
• Honig P. K., Wortham D. C., Zamani K., Conner D. P., Mullin J. C., Cantilena L. R. Terfenadine-ketoconazole interaction. J. Am. Med. Assoc. 1993; 269: 1513–1518
   PubMed Web of Science ®Google Scholar
• Burkhart G. A., Sevka M. J., Temple R., Honig P. K. Pharmacoepidemiology and drug utilization. Clin. Pharmacol. Ther. 1997; 61: 93–96
   PubMedGoogle Scholar
• Honig P. K., Wortham D. C., Zamani K., Mullin J. C., Conner D. P., Cantilena L. R. The effect of fluconazole on the steady-state pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine in humans. Clin. Pharmacol. Ther. 1993; 53: 630–636
   PubMed Web of Science ®Google Scholar
• Pohjola-Sintonen S., Viitasalo M., Toivonen L., Neuvonen P. Itraconazole prevent terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia. Eur. J. Clin. Pharmacol. 1993; 45: 191–193
   PubMed Web of Science ®Google Scholar
• Honig P. K., Wortham D. C., Hull R., Zamani K., Smith J. E., Cantilena L. R. Itraconazole affects single-dose terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics. J. Clin. Pharmacol. 1993; 33: 1201–1206
   PubMed Web of Science ®Google Scholar
• Markham A., Wagstaff A. J. Fexofenadine. Drugs 1998; 55: 269–274
   PubMed Web of Science ®Google Scholar
• Simons F. E. R., Simons K. J. The pharmacology and use of H1-receptor-antagonist drugs. N. Engl. J. Med. 1994; 330: 1664–1670
   Google Scholar
• Wood S. G., John B. A., Chasseaud L. F., Yeh J., Chung M. The metabolism and pharmacokinetics of 14C-cetirizine in humans. Ann. Allergy 1987; 59: 31–34
   PubMedGoogle Scholar
• Cetirizine challenges other antihistamines in allergic rhinitis and chronic idiopathic urticaria. Drugs Ther. Perspect 1994; 3(8)1–4
   Google Scholar
• Von Rosenstiel N. A., Adam D. Macrolide antibacterials. Drug interactions of clinical significance. Drug Safety 1995; 13: 105–122
   PubMed Web of Science ®Google Scholar
• Lefebvre R. A., Van Peer A., Woestenborghs R. Influence of itraconazole on the pharmacokinetics and electrocardiographic effects of astemizole. Br. J. Clin. Pharmacol. 1997; 43: 319–322
   PubMed Web of Science ®Google Scholar
• Lavrijsen K., Van Houdt J., Meuldermans W., Janssens M., Heykants J. The interaction of ketoconazole, itraconazole and erythromycin with the in vitro metabolism of antihistamines in human liver microsomes. Allergy 1993; 48: 34
   Google Scholar
• D’Mello A. P., D’Souza M. J., Bates T. R. Pharmacokinetics of ketoconazole–antipyrine interaction. Lancet 1985; 2(8448)209–210
   PubMed Web of Science ®Google Scholar
• Daneshmend T. K., Warnock D. W., Ene M. D., et al. Multiple dose pharmacokinetics of ketoconazole and their effects on antipyrine kinetics in man. J. Antimicrob. Chemother. 1983; 12: 185–188
   PubMed Web of Science ®Google Scholar
• Dockens R. C., Rapoport D., Roberts D., Greene D. S., Barbhaiya R. H. Lack of an effect of nefazodone on the pharmacokinetics and pharmacodynamics of theophylline during concurrent administration in patients with chronic obstructive pulmonary disease. Br. J. Clin. Pharmacol. 1995; 40: 598–601
   PubMed Web of Science ®Google Scholar
• Rasmussen B. B., Brosen K. Theophylline has no advantages over caffeine as a putative model drug for assessing CYPIA2 activity in humans. Br. J. Clin. Pharmacol. 1997; 43: 253–258
   PubMed Web of Science ®Google Scholar
• Konishi H., Morita K., Yamaji A. Effect of fluconazole on theophylline disposition in humans. Eur. J. Clin. Pharmacol. 1994; 46: 309–312
   PubMed Web of Science ®Google Scholar
• McKillop D., Butters C. J., Hill S. J., Simons P. J., Edwards T. L., Doughty S. E. Enzyme-inducing effects of bicalutamide in mouse, rat and dog. Xenobiotica 1998; 28: 465–478
   PubMed Web of Science ®Google Scholar
• Thalhammer F., Hollenstein U. M., Locker G. J., et al. Azithromycin-related toxic effects of digitoxin. Br. J. Clin. Pharmacol. 1998; 45: 91–92
   PubMed Web of Science ®Google Scholar
• Alexander B. D., Perfect J. A. Antifungal resistance trends towards the year 2000. Drugs 1997; 54: 657–678
   PubMed Web of Science ®Google Scholar
• Miners J. O., Birkett D. J. Cytochrome P4502C9: An enzyme of major importance in human drug metabolism. Br. J. Clin. Pharmacol. 1998; 45: 525–538
   PubMed Web of Science ®Google Scholar
• Salphati L., Benet L. Z. Effect of ketoconazole on digoxin absorption and disposition in rat. Pharmacology 1998; 56: 308–313
   PubMed Web of Science ®Google Scholar
• Chan J. D. Pharmacokinetic drug interactions of vinca alkaloids: Summary of case reports. Pharmacotherapeutics 1998; 18: 1304–1307
   Google Scholar
• Chang Y., Hsieh Y., Izumi T., Benet L. Z. Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male SD rats. J. Pharm. Exp. Ther. 1998; 287: 246–252
   PubMed Web of Science ®Google Scholar
• Coleman M. D., Scott A. K., Breckenridge A. M., Park B. K. The use of cimetidine as a selective inhibitor of dapsone N-hydroxylation in man. Br. J. Clin. Pharmacol. 1990; 30: 761–767
   PubMed Web of Science ®Google Scholar
• Coleman M. D., Rhodes L. E., Scott A. K., et al. The use of cimetidine to reduce dapsone-dependent methaemoglobinaemia in dermatitis herpetiformis. Br. J. Clin. Pharmacol. 1992; 34: 244–249
   PubMed Web of Science ®Google Scholar
• Rhodes L. E., Tingle M. D., Park B. K., Chu P., Verbov J. L., Friedmann P. S. Cimetidine improves the therapeutic/toxic ratio of dapsone in patients on chronic dapsone therapy. Br. J. Dermatol. 1995; 132: 257–262
   PubMed Web of Science ®Google Scholar
• Hargreaves J. A., Jezequel S., Houston J. B. Effect of azole antifungals on human microsomal metabolism of diclofenac and midazolam. Br. J. Clin. Pharmacol. 1994; 38: 175P
   Google Scholar
• Leemann T., Transon C., Dayer P. Cytochrome P450TB (CYP2C): A major monooxygenase catalyzing diclofenac 4′-hydroxylation in human liver. Life Sci. 1993; 52: 29–34
   PubMed Web of Science ®Google Scholar
• Mancy A., Broto P., Dijols S., Dansette P. M., Mansuy D. The substrate binding site of human liver cytochrome P450 2C9: An approach using designed tienilic acid derivatives and molecular modeling. Biochemistry 1995; 34: 10,365–10,375
   Google Scholar
• Tomlinson E. S., Maggs J. L., Park B. K., Back D. J. Dexamethasone metabolism in vitro: Species differences in 6-hydroxylation. Br. J. Clin. Pharmacol. 1996; 41: 462–463P
   Google Scholar
• Pichard L., Fabre I., Fabre G., et al. Cyclosporin and drug interactions. Drug Metab. Disp. 1990; 18: 595–606
   PubMed Web of Science ®Google Scholar